Published in Medical Letter on the CDC and FDA, August 31st, 2008
"The level of protection was dependent upon the challenge dose of Y. pestis and the timing of AGP therapy....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.